Mutagenic bioassay of certain pharmacological drugs. I. Thiabendazole (TBZ).
This report describes the chromosomal damage produced by 2-(4'-thiazolyl)benzimidazole or thiabendazole (TBZ) evaluated by "in vivo" and "in vitro" cytogenetic tests. The doses assayed in adult mice by the sister-chromatid exchange (SCE) and micronucleus tests were: 50, 100 and 200 mg/kg body weight; these are within the range of those used in human antihelminthic treatments. SCE frequency was increased only in the last dose (p less than 0.05). A significant increase of micronucleated cells was shown in the 3 doses assayed (p less than 0.001). A marked increase in abnormal anaphase-telophase cells was only detected with the two highest concentrations assayed (0.60-0.24 microgram/ml) p less than 0.01 and p less than 0.05 respectively. The observed genotoxic effects of this compound indicate that TBZ itself is a mutagenic agent.
D000705:Anaphase / Q000187:drug effects; D000818:Animals; D002460:Cell Line; D002467:Cell Nucleus / Q000187:drug effects* / Q000648:ultrastructure; D006224:Cricetinae; D005260:Female; D005347:Fibroblasts / Q000187:drug effects; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009152:Mutagenicity Tests; D012854:Sister Chromatid Exchange / Q000187:drug effects*; D013692:Telophase / Q000187:drug effects; D013827:Thiabendazole / Q000008:administration & dosage / Q000494:pharmacology*
D013827:Thiabendazole